Durable radiologic and clinical disease stability beyond PSA progression in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone acetate (AA)

被引：0
|
作者：
Bianchini, Diletta
Sandhu, Shahneen Kaur
Cassidy, Amy Mulick
Zivi, Andrea
Mezynski, Janusz
Mukherji, Deborah
Pezaro, Carmel Jo
Reid, Alison Helen
Oommen, Nikhil Babu
Olmos, David
Omlin, Aurelius Gabriel
Sarvadikar, Ajit
Thompson, Emilda
Hunt, Joanne
Sheridan, Elizabeth
Attard, Gerhardt
De Bono, Johann Sebastian
机构：
[1] Royal Marsden Hosp, Sutton, Surrey, England
[2] Inst Canc Res, Sutton, Surrey, England
[3] Royal Marsden Fdn Trust, Sutton, Surrey, England
[4] Royal Marsden Hosp, Dublin, Ireland
[5] Royal Marsden NHS Fdn Trust, London, England
[6] Inst Canc Res, London SW3 6JB, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4553
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Erratum to Abiraterone acetate: in metastatic castration-resistant prostate cancer
    L. P. H. Yang
    Drugs, 2012, 72 (2) : 192 - 192
  • [32] Statin Use and Survival in Patients with Metastatic Castration-resistant Prostate Cancer Treated with Abiraterone Acetate
    Di Lorenzo, Giuseppe
    Sonpavde, Guru
    Pond, Gregory
    Lucarelli, Giuseppe
    Rossetti, Sabrina
    Facchini, Gaetano
    Scagliarini, Sarah
    Carteni, Giacomo
    Federico, Piera
    Daniele, Bruno
    Morelli, Franco
    Bellelli, Teresa
    Ferro, Matteo
    De Placido, Sabino
    Buonerba, Carlo
    EUROPEAN UROLOGY FOCUS, 2018, 4 (06): : 874 - 879
  • [33] Abiraterone Acetate (Zytiga) for Metastatic Castration-Resistant Prostate Cancer
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2011, 53 (1370): : 63 - 64
  • [34] Prognostic value of PSA progression in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated in the COU-AA-302 trial.
    Lorente, David
    Lozano, Rebeca
    de Velasco, Guillermo
    De Julian, Maria
    Rodrigo, Miguel
    Sanchez, Angel L.
    Di Capua, Carlos
    Castro, Elena
    Sanchez Hernandez, Alfredo
    Olmos, David
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [35] Effects of 6 months of abiraterone acetate (AA) on muscle and adipose mass in men with metastatic castration-resistant prostate cancer (mCRPC).
    Brondfield, Samuel Craig
    Weinberg, Vivian K.
    Koepfgen, Kathryn M.
    Molina, Arturo
    Ryan, Charles J.
    Small, Eric Jay
    Harzstark, Andrea Lynne
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [36] Effects of 6 months of abiraterone acetate (AA) on muscle and adipose mass in men with metastatic castration-resistant prostate cancer (mCRPC)
    Brondfield, Samuel Craig
    Weinberg, Vivian K.
    Koepfgen, Kathryn M.
    Molina, Arturo
    Ryan, Charles J.
    Small, Eric Jay
    Harzstark, Andrea Lynne
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (05)
  • [37] Association between PSA declines at 4 weeks and OS in patients treated with abiraterone acetate (AA) for metastatic castration resistant prostate cancer (mCRPC) after docetaxel.
    Rescigno, Pasquale
    Lorente, David
    Ferraldeschi, Roberta
    Bianchini, Diletta
    Sideris, Spyridon
    Zafeiriou, Zafeiris
    Smith, Alan David
    Mehra, Niven
    Grist, Emily
    Jayaram, Anuradha
    Kolinsky, Michael Paul
    Lopez, Raquel Perez
    Mateo, Joaquin
    Parker, Chris
    Dearnaley, David Paul
    Hall, Emma
    Tunariu, Nina
    Attard, Gerhardt
    De Bono, Johann Sebastian
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)
  • [38] Is there an additional health-related quality of life (HRQL) benefit with abiraterone acetate (AA) in metastatic castration-resistant prostate cancer (mCRPC) beyond that mediated by clinical endpoints?
    Cella, David
    Molina, Arturo
    Gagnon, Dennis D.
    Espindle, Derek
    Hao, Yanni
    Basch, Ethan M.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [39] Phase 1b study of abiraterone acetate (AA) and docetaxel (D) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
    Tagawa, Scott T.
    Posadas, Edwin M.
    Bruce, Justine Yang
    Lim, Emerson A.
    Petrylak, Daniel Peter
    Peng, Weimin
    Maul, Raymond Scott
    Smit, Hans W.
    Tran, Namphuong
    Nanus, David M.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [40] A multicenter population-based experience with abiraterone acetate (AA) in patients with metastatic castration resistant prostate cancer (mCRPC)
    Clayton, Ravinder
    Heng, Daniel Yick Chin
    Wu, Jackson S. Y.
    Zielinski, Rob
    North, Scott A.
    Emmenegger, Urban
    Hotte, Sebastien J.
    Al-Shamsi, Humaid Obaid
    Chen, Leo
    Eigl, Bernhard J.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
12345